Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Adult T-cell leukemia/lymphoma (ATLL)

Written2005-05Antonio Cuneo, Gianluigi Castoldi
Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9827/3 Adult T-cell leukaemia/lymphoma
Atlas_Id 2032

Clinics and Pathology

Phenotype / cell stem origin This is a T-cell lymphoid neoplasia caused by HTLV1 infection. The phenotype is CD3+, CD5+, CD7- with positivity for the CD4 and CD25 molecules in the majority of the cases.
Etiology Pathogenesis of the disease: ATLL is associated with HTLV-1 infection of the tumour clone in 100% of the cases. The interval between HTLV-1 infection and the onset of lymphoma is long (10-40 years) and only <5% of infected people actually develops the disease. HTLV-1 produces a trans-regulatory protein (Tax) inducing interleukin-2 (IL-2) and IL-2 receptor expression and consequent polyclonal CD4 cell growth. This T-cell population is at risk for the development of genetic and cytogenetic changes leading to lymphoma.
Epidemiology The disease affects adult people. Clusters were observed in Japan and in the Caribbean; sporadic cases were reported in Western countries.
Clinics The disease usually runs an aggressive course, with peripheral blood and bone marrow involvement, diffuse adenopathies, hepatomegaly, bone lesions and hypercalcemia. Smouldering or chronic forms were also observed.
Pathology The lymph node architecture is effaced by a diffuse proliferation of small and large lymphoid cells having pleomorphic cytological features. In the peripheral blood the neoplastic cells often display a lobated nucleus (flower cells); diffuse bone marrow infiltration is found in virtually all cases.
Treatment Multiagent chemotherapy usually attains only partial, short lasting responses. Highly active anti viral therapy with zidouvidine and interferon-alpha may be beneficial in some cases.
Prognosis Patients with aggressive disease usually survive less than 1 year; less than 10% of the patients survive more than 5 years. Longer survival (> 2 years) can be observed in rare patients presenting a chronic or a smouldering form.

Cytogenetics

Note The karyotype almost invariably shows a high degree of complexity and variability. Aneuploidy and more than 6 chromosome breaks were observed in the majority of cases. The most frequent gains include trisomy 3, trisomy 8, trisomy 9 and trisomy 21; monosomies involve chromosome 4, 8, 10 and 22. Breakpoints clusters are found at 1p and 1q, at 3q, 6q, 7q, 10p, 12q, 13q, 14q, 17p and 21p. Multiple breaks and aberrations of some of these chromosome regions may predict for an inferior outcome.
Cytogenetics Molecular Comparative genomic hybridization (CGH) studies revealed that the most frequent regions of DNA gains are located at 14q, 7q and 3p; whereas frequent losses involve sequences at 6q and 13q. Gain of 14q32 may be a recurrent specific abnormality in ATLL. Aggressive forms display more genomic aberrations than chronic forms. The number of chromosomal imbalances correlates with clinical outcome. Different hybridization patterns, suggesting clonal evolution, can be observed when analysing material from different sites or material taken at different time points in the same patient.
Upregulation of gene encoding for ribosomal proteins, proteosome subunits, translation factors was identified in acute vs chronic phases of the disease. Many of these genes are located in regions amplified by chromosome rearrangements. Downregulation of genes involved in immune response was also documented.

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki.
Itoyama T, Chaganti RS, Yamada Y, Tsukasaki K, Atogami S, Nakamura H, Tomonaga M, Ohshima K, Kikuchi M, Sadamori N
Blood. 2001 ; 97 (11) : 3612-3620.
PMID 11369658
 
Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis.
Tsukasaki K
Journal of clinical immunology. 2002 ; 22 (2) : 57-63.
PMID 11998893
 
Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays.
Tsukasaki K, Tanosaki S, DeVos S, Hofmann WK, Wachsman W, Gombart AF, Krebs J, Jauch A, Bartram CR, Nagai K, Tomonaga M, Said JW, Koeffler HP
International journal of cancer. Journal international du cancer. 2004 ; 109 (6) : 875-881.
PMID 15027121
 

Citation

This paper should be referenced as such :
Cuneo, A ; Castoldi, GL
Adult T-cell leukemia/lymphoma (ATLL)
Atlas Genet Cytogenet Oncol Haematol. 2005;9(3):236-237.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/AdultTLeukLymphID2032.html


Other genes implicated (Data extracted from papers in the Atlas) [ 18 ]

Genes AKT1 BMI1 BUB1 CCNB1 DPP4 ERG EZH2 IDO1 IL21R IRF4
PCNA PTPN6 RAN RTN4 TRA TRD TERF2 TXN

External links

COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMapTopo ( C42) Morph ( 9827/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseAdult T-cell leukemia/lymphoma (ATLL)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:18:20 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.